Literature DB >> 16200179

Anthrax: a continuing concern in the era of bioterrorism.

Stefan Riedel1.   

Abstract

Anthrax, a potentially fatal infection, is a virulent and highly contagious disease. It is caused by a gram-positive, toxigenic, spore-forming bacillus: Bacillus anthracis. For centuries, anthrax has caused disease in animals and, although uncommonly, in humans throughout the world. Descriptions of this naturally occurring disease begin in antiquity. Anthrax is primarily a disease of herbivores, which are infected by ingestion of spores from the soil. With the advent of modern microbiology, Pasteur developed the first successful anthrax vaccine in 1881. The incidence of the disease has continually decreased since the late 19th century, and animal vaccination programs drastically reduced the animal mortality from the disease. However, anthrax spores continue to be documented in soil samples from throughout the world. Research on anthrax as a biological weapon began more than 80 years ago, and today at least 17 nations are believed to have offensive biological weapons programs that include anthrax. Recent events in the USA have shown how society is affected by both hoax and real threats of anthrax bioweapons. This fourth article in the series on weapons of biowarfare/bioterrorism summarizes the historical background of anthrax as well as clinical and laboratory information useful for bioterrorism preparedness.

Entities:  

Year:  2005        PMID: 16200179      PMCID: PMC1200731          DOI: 10.1080/08998280.2005.11928074

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  44 in total

Review 1.  Anthrax.

Authors:  T C Dixon; M Meselson; J Guillemin; P C Hanna
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

2.  US military face punishment for refusing anthrax vaccine.

Authors:  K Morris
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

3.  Bioterrorism: an update with a focus on anthrax.

Authors:  Philip S Brachman
Journal:  Am J Epidemiol       Date:  2002-06-01       Impact factor: 4.897

4.  Gastric anthrax with massive ascites.

Authors:  W Dutz; F Saidi; E Kohout
Journal:  Gut       Date:  1970-04       Impact factor: 23.059

5.  Familial occurrence of anthrax in Eastern Algeria.

Authors:  D Abdenour; B Larouze; M Dalichaouche; M Aouati
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

6.  Inhalation anthrax.

Authors:  P S Brachman
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

7.  Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid.

Authors:  I Uchida; T Sekizaki; K Hashimoto; N Terakado
Journal:  J Gen Microbiol       Date:  1985-02

8.  Inhalation anthrax in a home craftsman.

Authors:  S C Suffin; W H Carnes; A F Kaufmann
Journal:  Hum Pathol       Date:  1978-09       Impact factor: 3.466

9.  Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis.

Authors:  T Sirisanthana; N Navachareon; P Tharavichitkul; V Sirisanthana; A E Brown
Journal:  Am J Trop Med Hyg       Date:  1984-01       Impact factor: 2.345

Review 10.  The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

Authors:  A F Kaufmann; M I Meltzer; G P Schmid
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

View more
  10 in total

1.  Crystal structures of putative phosphoglycerate kinases from B. anthracis and C. jejuni.

Authors:  Heping Zheng; Ekaterina V Filippova; Karolina L Tkaczuk; Piotr Dworzynski; Maksymilian Chruszcz; Przemyslaw J Porebski; Zdzislaw Wawrzak; Olena Onopriyenko; Marina Kudritska; Sarah Grimshaw; Alexei Savchenko; Wayne F Anderson; Wladek Minor
Journal:  J Struct Funct Genomics       Date:  2012-03-10

2.  Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood.

Authors:  Raymond E Biagini; Deborah L Sammons; Jerome P Smith; Barbara A MacKenzie; Cynthia A F Striley; John E Snawder; Shirley A Robertson; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2006-05

3.  A Learner-led, Discussion-based Elective on Emerging Infectious Disease.

Authors:  Clinton Mathias
Journal:  Am J Pharm Educ       Date:  2015-08-25       Impact factor: 2.047

4.  Treating Anthrax-Induced Meningitis in Rabbits.

Authors:  Amir Ben-Shmuel; Itai Glinert; Assa Sittner; Elad Bar-David; Josef Schlomovitz; Tal Brosh; David Kobiler; Shay Weiss; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

5.  A Whole-Genome-Based Gene-by-Gene Typing System for Standardized High-Resolution Strain Typing of Bacillus anthracis.

Authors:  Mostafa Y Abdel-Glil; Alexandra Chiaverini; Giuliano Garofolo; Antonio Fasanella; Antonio Parisi; Dag Harmsen; Keith A Jolley; Mandy C Elschner; Herbert Tomaso; Jörg Linde; Domenico Galante
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

6.  Evaluation of New Dihydrophthalazine-Appended 2,4-Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New Pincer Complex.

Authors:  Nagendra Prasad Muddala; Baskar Nammalwar; Subhashini Selvaraju; Christina R Bourne; Mary Henry; Richard A Bunce; K Darrell Berlin; Esther W Barrow; William W Barrow
Journal:  Molecules       Date:  2015-04-21       Impact factor: 4.411

7.  Using old antibiotics to treat ancient bacterium-β-lactams for Bacillus anthracis meningitis.

Authors:  Assa Sittner; Amir Ben-Shmuel; Itai Glinert; Elad Bar-David; Josef Schlomovitz; David Kobiler; Shay Weiss; Haim Levy
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

8.  Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis.

Authors:  Baskar Nammalwar; N Prasad Muddala; Christina R Bourne; Mary Henry; Philip C Bourne; Richard A Bunce; Esther W Barrow; K Darrell Berlin; William W Barrow
Journal:  Molecules       Date:  2014-03-17       Impact factor: 4.411

Review 9.  The antigenome: from protein subunit vaccines to antibody treatments of bacterial infections?

Authors:  Carmen Giefing; Eszter Nagy; Alexander von Gabain
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

10.  Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.

Authors:  Chad W Stratilo; Scott Jager; Melissa Crichton; James D Blanchard
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.